Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Cutaneous and gastrointestinal symptoms in two patients with systemic mastocytosis successfully treated with omalizumab

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Insulin Independence in Newly Diagnosed Type 1 Diabetes Patient following Fenofibrate Treatment

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Cowden Syndrome and Concomitant Pulmonary Neuroendocrine Tumor: A Presentation of Two Cases

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Successful and Safe Treatment of Chronic Spontaneous Urticaria with Omalizumab in a Woman during Two Consecutive Pregnancies

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. PET/MRI for Preoperative Planning in Patients with Soft Tissue Sarcoma: A Technical Report of Two Patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Massive fetomaternal hemorrhage caused by an intraplacental choriocarcinoma: a case report

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskning

  1. Ciclosporin

    Publikation: Bog/antologi/afhandling/rapportRapportRådgivning

  2. Factors associated with citation of original articles in 5 high-impact-factor dermatology journals

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Patients with a familial predisposition to hidradenitis suppurativa have a distinct clinical phenotype

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Online Patient Recruitment in Clinical Trials: Systematic Review and Meta-Analysis

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

Vis graf over relationer
The pathogenesis of mastocytosis is not well defined and thus treatment remains challenging and remains on a palliative basis. We present two cases (a 48-year-old woman and a 57-year-old man) with indolent systemic mastocytosis in whom omalizumab (anti-IgE) reduced gastrointestinal and cutaneous symptoms significantly. This observation provides additional insight into the effects of omalizumab on systemic mastocytosis.
OriginalsprogEngelsk
TidsskriftCase reports in medicine
Vol/bind2015
Sider (fra-til)903541
ISSN1687-9627
DOI
StatusUdgivet - 2015

ID: 46234663